Ambrx Reviews

If you like spending your life with your head to the ground, with no prospect of ever enjoying your work or being rewarded for it, then by all means, work there! From the very beginning, the brightest employees were shamelessly taken advantage of by the directionless management (save IP department, which was great) and a passive board. In 2010, Schultz "took over" and forced out the remaining experienced research leaders with his infamous arrogance, business myopia and blatant favoritism. Only the politicians survived. One of his shifty buddies is now CSO, another is helping him fly his new plane at Calibr. All he managed to do was to transform the company into yet another extension of his lab, with no accountability from anyone in charge whatsoever (reminds anyone of the GNF story?). To top it all off, the final inept board failed to go through with an IPO when the company still had value to the market, and thought of nothing better than to sell it to China instead, ripping off common shareholders in the process (golden parachutes for the officers, naturally). The only product that will ever come out of this joint is the one co-developed with Lilly animal health, mark these words. ADC's are falling by the wayside already, and since Ambrx is heavily ADC-centered, it will not survive, once major pharma's start pulling out en-masse. Talk about miserable failure of a great idea, what a sad joke. Calibr may soon become the next Ambrx, with the same bunch of narcissistic incompetent posers in charge.